Key clinical evidence: Large phase 3 programscommonly referred to as the SURPASS studies for diabetes and SURMOUNT studies for obesitydemonstrated robust improvements in HbA1c and substantial, dose-dependent weight loss compared with placebo and many active comparators
GST M1 polymorphism associates with DNA oxidative damage and mortality among hemodialysis patients
Monitoring and follow-up should continue as recommended for tirzepatide therapy, typically including assessment of glycemic control (A1C), weight, gastrointestinal tolerability, and screening for potential adverse effects
Frequency is based on your individual goals and medical or healthcare provider recommendation, but many patients receive injections weekly or bi-weekly
2021 An interactive 3D model rendered from the compound record rotate and explore its structure
There are several hypotheses for the second signal activation and further investigations are necessary in order to find whether is there any common component for all second signals described, for example, the release of ROS 93